Project Grant R01NS141790
- Federal Project Grant Award Summary The University of Florida received a $422,125 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 15, 2025, through July 31, 2027. The grant supports fundamental neuroscience research investigating the role of the DNAJC12 protein chaperone in dopamine biosynthesis and regulation. Specifically,...
- Federal Grant Award Summary Florida International University received a $1,319,674 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective January 26, 2026, through December 31, 2030. The award funds research to develop CRISPR/dCas9 (Dead CRISPR Associated Protein 9)-targeted histone demethylation therapies for Friedreich's Ataxia (FRDA),...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $599,005 project grant to the University of Miami's Office of Research Administration on August 21, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research will be conducted in Florida and is scheduled for completion by July 31, 2030. This award supports investigator-initiated basic and translational research...
- Federal Grant Award Summary Oregon Health & Science University received a $148,050 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective December 1, 2025, through May 31, 2028. This award supports investigator-initiated basic research to advance understanding of neuronal development and disease mechanisms relevant to neurodevelopmental...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $175,227 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program to The Research Foundation for the State University of New York, with performance conducted in Buffalo, NY. The award was obligated on September 1, 2025, with an ultimate completion date of March 25, 2027. The project delivers research and analysis...
- Federal Project Grant Award Summary The University of Washington received a $147,486 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 27, 2025, with a completion date of May 15, 2028. The award supports doctoral-level research investigating the function of a previously uncharacterized ciliary protein in neural development, with...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $637,820 to the Research Institute at Nationwide Children's Hospital on June 11, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project grant supports forward genetic analysis research designed to identify novel genes influencing forebrain neurodevelopment, with specific emphasis on cortical structure, lamination, and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $112,297 to The Regents of the University of Colorado (University of Colorado-Denver) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award, effective August 1, 2025, through July 31, 2027, funds research investigating the impact of nutritional status—specifically docosahexaenoic acid (DHA) deficiency—on brain...
- Federal Grant Award Summary Emory University received a $575,485 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective February 1, 2026, through January 31, 2031. This award supports fundamental and translational research investigating the role of BCL11A, a zinc-finger transcription factor, in neuronal function and neurological disease...
- Federal Grant Award Summary Florida State University received a $413,694 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 15, 2025, with completion targeted for July 31, 2027. The award funds fundamental neuroscience research investigating the neural mechanisms by which social touch influences brain development during the infant...
The University of Florida's Division of Sponsored Research received a $423,750 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective March 16, 2026, through February 28, 2031. The award supports research to identify approved drugs for treating Brain-Derived Neurotrophic Factor (BDNF) insufficiency, a condition affecting individuals with WAGR (Wilms Tumor, Aniridia, Genitourinary Abnormalities, and Mental Retardation) syndrome. The project focuses on developing therapeutic interventions to increase BDNF expression in patients exhibiting BDNF haploinsufficiency-related complications, including severe obesity, intellectual disability, autism, and impaired pain perception. The research team has developed an innovative phenotypic assay utilizing a novel BDNFNLUC mouse strain, in which nano luciferase is inserted into the BDNF locus, enabling highly sensitive and reproducible detection of BDNF expression in 384-well plate formats. This assay platform will be leveraged to screen and identify existing approved drugs capable of enhancing BDNF expression, potentially enabling rapid translational advancement toward clinical applications for WAGR patients with BDNF insufficiency. The work integrates basic neuroscience research with translational drug discovery to address a critical unmet medical need in a rare disease population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $423.8k | 3/16/26 |